Comparative Pharmacology
Head-to-head clinical analysis: DELZICOL versus ROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELZICOL versus ROWASA.
DELZICOL vs ROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Delzicol is a prodrug of mesalamine (5-aminosalicylic acid). It is converted to mesalamine in the colon by bacterial azoreduction. Mesalamine reduces inflammation in the colon by inhibiting prostaglandin production via cyclooxygenase inhibition and decreasing leukotriene synthesis via lipoxygenase pathway. It also scavenges reactive oxygen species and inhibits cytokine production.
5-aminosalicylic acid (5-ASA) inhibits prostaglandin and leukotriene synthesis, reduces neutrophil chemotaxis, and scavenges reactive oxygen species, thereby exerting anti-inflammatory effects on the colonic mucosa.
800 mg orally 3 times daily for ulcerative colitis; mesalamine 4 g retention enema once daily or 4 g foam once daily for proctosigmoiditis.
Rectal suspension enema: 4 g (60 mL) once daily at bedtime, retained for at least 8 hours. Rectal suppository: 500 mg twice daily (one in the morning and one at bedtime).
None Documented
None Documented
The terminal elimination half-life of mesalamine is approximately 0.5-1.5 hours after oral administration. For the acetylated metabolite, it is 5-10 hours. The short half-life necessitates multiple daily dosing for sustained colonic anti-inflammatory effect.
Terminal elimination half-life of mesalamine (5-ASA) is approximately 0.5-2 hours; N-acetyl-5-ASA half-life is 5-10 hours. Rectal administration prolongs local retention without altering systemic half-life.
Approximately 40-50% of the absorbed dose is excreted renally as mesalamine (5-ASA) and its acetylated metabolite (N-Ac-5-ASA). Fecal excretion accounts for the remainder, including unabsorbed drug and biliary elimination.
Renal: approximately 78% (primarily N-acetyl-5-ASA and unchanged 5-ASA). Fecal: approximately 20% (unabsorbed drug). Biliary: negligible (<1%).
Category C
Category C
Aminosalicylate
Aminosalicylate